CE Mark achieved for wearable device

View printer-friendly version Brisbane, Australia, 2 March 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has...

Update on licencing agreement with Workplace Medicine Australia

View printer-friendly version Brisbane, Australia, 26 February 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provides an update on its...

Pre-Submission package lodged with the US FDA

View printer-friendly version Brisbane, Australia, 10 February 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has...

ResApp receives $801,738 in R&D tax incentive refund and grant

View printer-friendly version Brisbane, Australia, 4 February 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that it has...

ResApp strengthens patent position in Europe

View printer-friendly version Brisbane, Australia, 2 February 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that the...

ResApp appoints VP, Commercial to progress growth strategy

View printer-friendly version Mike Connell appointed as VP, Commercial to lead global commercial activities Mr Connell has extensive experience in sales, marketing and strategy across the pharmaceutical, healthcare and FMCG industries Mr Connell has previously held...